MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
CERT stock logo

CERT

Certara, Inc.

$5.41
-0.09
 (-1.64%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  861.669M
Shares Outstanding:  132.408M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Healthcare Information Services
   
CEO:  Jon Resnick
Full Time Employees:  1487
Address: 
100 Overlook Center
Princeton
NJ
8540
US
Website:  https://www.certara.com
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers’ new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/05 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue354,337385,148418,838
Gross Profit213,315230,632257,712
EBITDA23,84472,36983,910
Operating Income-40,774-1,73121,016
Net Income-55,357-12,051-1,595

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets1,563,1401,575,1041,556,582
Total Liabilities516,300516,448493,787
Total Stockholders Equity1,046,8401,058,6561,062,795
Total Debt302,567311,89711,401
Cash and Cash Equivalents234,951179,183189,392

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow82,75580,46696,325
Capital Expenditure-15,322-1,625-1,760
Free Cash Flow67,43378,84194,565
Net Income-55,357-12,051-1,595
Net Change in Cash-4,737-55,76810,209

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2029Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)428,855.026Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)462,040.134Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)450,900Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)79,374.823Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)85,516.904Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)83,455.027Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)87,116.624Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)96,016.911Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)93,028.763Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)141,493.018Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)152,441.848Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)148,766.361Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.580Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.600Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.540Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
385.148M  ?P/S
 (TTM)
: 
2.36
?Net Income
 (TTM)
: 
-12051000  ?P/E
 (TTM)
: 
-625.49
?Enterprise Value
 (TTM)
: 
811.86M  ?EV/FCF
 (TTM)
: 
9.08
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0  ?ROIC
 (TTM)
: 
0
?Net Debt
 (TTM)
: 
132.714M  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
0.94  ?Current Ratio
 (TTM)
: 
2.05

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
12.02Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates CERT intrinsic value between $7.23 – $9.52 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate CERT Intrinsic Value

Common questions about CERT valuation

Is Certara, Inc. (CERT) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Certara, Inc. (CERT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is CERT a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CERT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is CERT’s P/E ratio?

You can see CERT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for CERT?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is CERT a good long-term investment?

Whether CERT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

CERT

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

-1.64
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 5.24   Year High: 15.38
Price Avg 50: 7.09   Price Avg 200: 9.67
Volume: 6.127M   Average Volume: 3.675M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026
09-04-2026 16:15
Certara to Report First Quarter 2026 Financial Results on May 11th, 2026
Certara to Participate in Upcoming Investor Conferences
27-02-2026 08:30
Certara to Participate in Upcoming Investor Conferences
Certara, Inc. (CERT) Q4 2025 Earnings Call Transcript
26-02-2026 13:37
Certara, Inc. (CERT) Q4 2025 Earnings Call Transcript
Certara, Inc. (CERT) Q4 Earnings Lag Estimates
26-02-2026 09:15
Certara, Inc. (CERT) Q4 Earnings Lag Estimates
Certara Stock Fell 23% After Earnings and This Fund Bought Up $3 Million Anyway
05-01-2026 13:17
Certara Stock Fell 23% After Earnings and This Fund Bought Up $3 Million Anyway
Earnings Estimates Moving Higher for Certara (CERT): Time to Buy?
08-12-2025 13:21
Earnings Estimates Moving Higher for Certara (CERT): Time to Buy?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read